Gyejigachulbutang (Gui-Zhi-Jia-Shu-Fu-Tang, Keishikajutsubuto, TJ-18) in Degenerative Knee Osteoarthritis Patients: Lessons and Responders from a Multicenter Randomized Placebo-Controlled Double-Blind Clinical Trial.
Myung Kwan KimJungtae LeemYoung Il KimEunseok KimYang Chun ParkJae-Uk SulHee-Geun JoSang-Hoon YoonJeeyong KimJu-Hyun JeonIn-Chul JungPublished in: Evidence-based complementary and alternative medicine : eCAM (2020)
GCB was not effective in primary outcome analysis. In exploratory subgroup analysis, GCB might be effective for individuals with BMI lower than 25 kg/m2 for the treatment of degenerative KOA. GCB may also help reduce the consumption of pain medication. Furthermore, research is required for our hypothesis. This trial is registered with KCT0003024.
Keyphrases
- double blind
- placebo controlled
- phase iii
- clinical trial
- phase ii
- knee osteoarthritis
- study protocol
- open label
- end stage renal disease
- chronic kidney disease
- healthcare
- chronic pain
- newly diagnosed
- body mass index
- randomized controlled trial
- ejection fraction
- spinal cord injury
- systemic lupus erythematosus
- rheumatoid arthritis
- emergency department
- prognostic factors
- disease activity
- neuropathic pain
- smoking cessation
- adverse drug